The Irvine, Calif.-based company also plans to grant underwriters a 30-day option to buy up to $11.3 million in shares of common stock.
Aerie reported that it plans to use the net proceeds from the offering to fund U.S. commercialization programs for its eye drugs, Rhopressa and Roclatan, as well as support development for its products in the pipeline.
The company is also reportedly working to build its own manufacturing plant in Ireland.
Aerie won an early FDA nod for its glaucoma drug, Rhopressa, in December last year. The FDA was slated to make a decision about the company’s eye drops in February.
The win for Aerie came after an expert panel voted 9-1 in the drug’s favor. Studies have found that Rhopressa lowers elevated intraocular pressure in the eye, but analysts have noted that the twice-daily generic timolol ophthalmic solution 0.5% is more effective for patients with severe cases of glaucoma.
Aerie’s next product, Roclatan, combines Rhopressa with the generic latanoprost. The company plans to submit that drug for approval with the FDA in Q2 of 2018.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.